Source-grounded facts extracted from REGENEREX PHARMA, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kenneth W. Perry departed as Chief Financial Officer at REGENEREX PHARMA, INC..
“As of June 5, 2026, the Company has commenced legal proceedings against its former Chief Financial Officer, Kenneth W. Perry (the "Former CFO"), in the matter of Regenerex Pharma, Inc. v. Kenneth W. Perry , Smith County Chancery Court, Case No. 2026-CV-8813.”
Don E. Ray was appointed as Interim Chief Financial Officer at REGENEREX PHARMA, INC..
“In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.”
Kenneth Perry was terminated as Chief Financial Officer at REGENEREX PHARMA, INC..
“Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.”
REGENEREX PHARMA, INC.: Changed fiscal year end from March 31 to December 31 (effective 2025-09-22).
“the Board of Directors (the “Board”) of Regenerex Pharma, Inc. (the “Company”) approved a change to the Company’s fiscal year end from March 31 to December 31”
Brent Wilson resigned as Chief Financial Officer at REGENEREX PHARMA, INC..
“Effective March 31, 2025, Mr. Brent Wilson resigned his position as Chief Financial Officer of the Company due to personal reasons.”
Kenneth W. Perry was appointed as Chief Financial Officer at REGENEREX PHARMA, INC..
“Effective March 31, 2025, Mr. Kenneth W. Perry has been appointed to serve as Chief Financial Officer for the company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.